Statements (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
prodrug |
| gptkbp:approvedBy |
gptkb:FDA
1995 |
| gptkbp:ATCCode |
J05AB11
|
| gptkbp:bioavailability |
54%
|
| gptkbp:brand |
gptkb:Valtrex
|
| gptkbp:CASNumber |
124832-27-5
|
| gptkbp:category |
antiviral drug
|
| gptkbp:cause |
gptkb:hemolytic_uremic_syndrome
thrombotic thrombocytopenic purpura renal impairment |
| gptkbp:chemicalFormula |
C13H20N6O4
|
| gptkbp:contraindication |
hypersensitivity to acyclovir
hypersensitivity to valacyclovir |
| gptkbp:developedBy |
GlaxoSmithKline
|
| gptkbp:eliminationHalfLife |
2.5-3.3 hours
|
| gptkbp:excretion |
renal
|
| https://www.w3.org/2000/01/rdf-schema#label |
valacyclovir
|
| gptkbp:KEGGID |
D02366
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits viral DNA polymerase
|
| gptkbp:meltingPoint |
220-225°C
|
| gptkbp:metabolism |
gptkb:acyclovir
|
| gptkbp:pregnancyCategory |
B (US)
B1 (Australia) |
| gptkbp:prescribes |
immunocompromised patients
HIV-positive patients organ transplant recipients |
| gptkbp:proteinBinding |
13-18%
|
| gptkbp:PubChem_CID |
135398744
CHEMBL1448 DB00577 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting abdominal pain dizziness fatigue headache rash |
| gptkbp:UNII |
61OQ44D3UN
|
| gptkbp:usedFor |
gptkb:chickenpox
shingles genital herpes herpes simplex virus infection herpes zoster varicella zoster virus infection cold sores |
| gptkbp:bfsParent |
gptkb:Herpes_Simplex
gptkb:virus |
| gptkbp:bfsLayer |
5
|